Pyoderma is one of the most common infectious dermatoses with a frequency of occurrence in the general structure of the skin disease to 43 % and 17,3 % for patients with mental health [2, 3]. Immunological disorders are one of the contributing factors to the development of pyoderma, including comorbid with schizophrenia [1, 2]. In this regard, the need for more in-depth study of disorders of the immune system in these patients is important.
Objective. Study the level of sL-selectin in the serum of patients with pyoderma comorbid schizophrenia.
Methods. Clinical and immunological study was performed in 40 patients with pyoderma comorbid with schizophrenia at the age of 18 to 70 years. To measure the level of human sL-selectin (leukocyte adhesion molecule-1) in human serum was used immunoassay method using horseradish peroxidase as the indicator enzyme (Bender MedSystems, Austria).
Results. Immunosorbent assay showed that the concentration of sL-selectin were significantly increased in patients with comorbid schizophrenia pyoderma, р < 0,001. In patients with schizophrenia without pyoderma sL-selectin levels were significantly increased compared with the parameters of healthy and 9,3 % was lower than in patients with comorbid schizophrenia pyoderma (1569,0 ± 120,7, 1423 ± 126,2 ng/ml, in patients with pyoderma comorbid schizophrenia and schizophrenia without pyoderma, respectively, 907,0 ± 148,3 ng/ml in healthy). The rise of sL-selectin may be a consequence of activation of neutrophils, which causes an increase in the number of adhesion molecules, and confirms that a compromised immune system are involved in the pathogenesis of schizophrenia, and pyoderma.
Conclusions. The results showed that elevated levels of sL-selectin detected in patients with comorbid schizophrenia pyoderma is a risk factor for the development of pyoderma and can be used as a criterion to judge violations of the immune system and to evaluate the effectiveness of therapy in these patients.
The work was submitted to International Scientific Conference «Innovative medical technologies», Russia (Moscow), May, 21-24, 2013, сame to the editorial office on 29.04.2013.